








According	 to	 Alzheimer’s	 Disease	 International	 (ADI),	 nearly	 50	 million	 people	
worldwide	were	living	with	dementia	in	2017,	and	this	number	is	expected	to	triple	
by	 2050.	 Despite	 years	 of	 research	 in	 this	 field,	 the	 root	 cause	 and	 mechanisms	
responsible	 for	 Alzheimer’s	 disease	 (AD)	 have	 not	 been	 fully	 elucidated	 yet.	
Moreover,	 promising	 preclinical	 results	 have	 repeatedly	 failed	 to	 translate	 into	





on	 green	 chemistry	 (natural	 phenolic	 molecules).	 These	 include	 therapeutic	
strategies	for	decreasing	amyloid-𝛽	(A𝛽)	production,	preventing	and/or	altering	A𝛽	
aggregation,	 and	 reducing	 oligomers	 cytotoxicity	 such	 as	 curcumin,	 (-)-
epigallocatechin-3-gallate	(EGCG),	morin,	resveratrol,	tannic	acid,	and	other	natural	
green	molecules.	We	also	examine	whether	consideration	should	be	given	to	potential	











Alzheimer’s	 disease	 ((AD)	 OMIM	 104300)	 is	 the	 most	 common	 age-related	
neurodegenerative	disorder.	 Its	clinical	symptoms	result	 from	the	deterioration	of	
selective	cognitive	domains,	particularly	those	related	to	memory	[1].	According	to	
Alzheimer’s	 Disease	 International	 (ADI),	 nearly	 50	 million	 individuals	worldwide	
were	living	with	dementia	in	2017,	and	this	number	is	projected	to	triple	by	2050	[2].	
Livingston	et	al.	[2]	have	calculated	that	over	a	third	of	all	cases	of	dementia	(derived	















most	 influential	 known	 risk	 factor	[9],	 with	 the	 exception	 of	 familial	 mutations	
leading	to	early-onset	amyloid	disease	(EOAD)	[10].	For	those	above	age	65,	the	risk	
of	 developing	 Alzheimer’s	 disease	 doubles	 every	 five	 years	[4].	 The	 two	 main	
pathological	hallmarks	of	AD	are	extracellular	amyloid-beta	plaques	 (A𝛽),	 a	4-kDa	
peptide	(39	to	43	amino	acids)	derived	 from	a	much	 larger	protein,	 the	80-kDa	𝛽-
amyloid	 precursor	 protein	 (APP)	[11],	 and	 intracellular	 structures	 composed	







and	 tau	 has	 been	 demonstrated	 in	 cellular	 and	 transgenic	 models,	 and	 crosstalk	
between	 these	molecules	has	been	demonstrated,	particularly	at	 the	synapse	[19].	




Amyloid	 Cascade	 Hypothesis,	 the	 primary	 influence	 driving	 AD	 pathogenesis	is	
accumulation	of	A𝛽	in	the	brain	[24].	In	the	revised	proposed	AD	model,	A𝛽	does	not	
directly	cause	cognitive	symptoms;	however,	as	a	dominant	driver	of	downstream	




properties	of	polyphenols	have	been	widely	studied,	 it	has	become	clear	 that	 their	
mechanisms	 of	 action	 go	 beyond	 the	 modulation	 of	 oxidative	 stress	[30].	 Indeed,	




















Despite	 decades	 of	 research,	 	 no	 drugs	 capable	 of	 slowing	 the	 progression	 of	
Alzheimer’s	disease	have	been	identified	[38].	Hence,	the	hypothesis	that	amyloid-𝛽	





























	A𝛽	 is	 found	 in	 lengths	 varying	 from	 39	 to	 43	 peptides	 in	 A𝛽	 plaques,	 with	 two	
dominant	species:	A𝛽$%	and	A𝛽$&.	A𝛽$&	oligomers	are	known	to	be	more	neurotoxic	
and	more	 aggregative	 than	A𝛽$%	 at	 comparable	 concentrations.	 The	 production	 of	
A𝛽$%	and	A𝛽$&	requires	the	proteolytic	processing	of	fully-modified	and	glycosylated	
amyloid	 precursor	 protein	 (APP)	 by	 𝛼-secretase,	 𝛽-secretase	 (BACE)	 and	 𝛾-










which	 is	 more	 hydrophobic	 and	 has	 a	 greater	 propensity	 to	 form	 fibrils	 than	
A𝛽$%	[46].	The	A𝛽$%	shows	significant	kinetic	solubility,	while	A𝛽$&	nucleates	much	
more	 rapidly	[46].	 The	 insoluble	 A𝛽	 in	 AD	 brain	 tissue	 is	 often	 predominantly	
A𝛽$&	[47].	The	predicted	solubility	is	0.4	𝜇M	for	A𝛽$%	and	0.04	𝜇M	for	A𝛽$&	[48],	which	
is	consistent	with	the	experimental	solubility	of	0.04	𝜇M	for	A𝛽$&	[49].	














a	higher	propensity	 than	A𝛽$%	dimer	to	 form	𝛽-strands	at	 the	central	hydrophobic	
core	(residues	17-21)	and	C-terminal	(residues	30-42),	two	crucial	segments	in	A𝛽	














greater	 than	 100	 kDa	[55],	 suggesting	 that	 A𝛽	 oligomers	 of	 various	 sizes	 are	
associated	 with	 the	 disease	[56].	 AD	 brains	 contained	 six	 times	 more	 wsA𝛽	 than	
control	brains	[55].	The	amount	of	wsA𝛽$&	 in	AD	brains	 is	approximately	50	times	
greater	 than	the	 level	of	soluble	A𝛽$&	 found	 in	the	cerebrospinal	 fluid	(CSF)	of	AD	
patients	[55].	 It	 was	 also	 reported	 that	 the	 formation	 of	 an	 oligomeric,	 𝛼-helix-
containing	assembly	is	a	key	step	in	A𝛽	 fibrillogenesis	[57].	The	pH	dependence	of	





Using	 single	 touch	 atomic	 force	microscopy	 (AFM),	monomeric	 A𝛽$&	 showed	 two	
distinct	types	of	oligomers,	low	molecular	weight	(MW)	oligomers	(~20kD,	tetramer)	
with	heights	of	1-2nm	and	high	MW	oligomers	(~56kD,	dodecamer)	with	heights	of	
3-5nm	[58].	 In	 both	 cases,	 the	 oligomers	 are	 disc-shaped	 with	 diameters	 of	 10-
15	nm	[58].	 Using	 a	 predictive	 coarse-grained	protein	 force	 field,	 Zheng	 et	 al.	[48]	
computed	and	compared	the	free	energy	landscapes	and	relative	stabilities	of	A𝛽$&	
and	A𝛽$%	 in	 their	monomeric	and	oligomeric	 forms	up	to	 the	octamer.	 Several	A𝛽	




further	aggregation	of	 these	 fibrils	generates	A𝛽	plaques.	Protofibrils	 formed	from	
A𝛽$%	 and	A𝛽$&	 show	 flexible	 fibers	 roughly	60-100	Å	in	diameter	[59].	A𝛽$&	 fibrils	
formed	more	rapidly	than	A𝛽$%	fibrils	[54].	Detailed	comparison	of	the	A𝛽$&	and	A𝛽$%	
fibril	 structures	 reveals	 that	 they	 share	 an	 axial	 twofold	 symmetry	 and	 a	 similar	
protofilament	 structure	[60].	 Amyloid	 fibrils	 are	 typically	 5-15	 nm	 in	 width,	
unbranched,	 straight	 over	 length	 scales	 approaching	 1	 micron,	 and	 often	 many	
microns	long	[49].	The	spacing	between	𝛽	strands	in	a	𝛽	sheet	is	0.46-0.48	nm	[49].	
Therefore,	 a	 one	 micron	 length	 of	 amyloid	 fibril	 typically	 contains	 thousands	 of	
protein	 molecules,	 with	 the	 exact	 number	 dependent	 on	 the	 number	 of	 cross-𝛽	
subunits,	the	number	of	𝛽	strand	segments	contributing	to	each	cross-𝛽	subunit	by	
one	 molecule,	 and	 the	 number	 of	 𝛽	 sheet	 layers	 within	 each	 subunit	[49].	 The	
structure	of	amyloid	fibrils	resembles	an	aircraft	cable,	in	which	3-6	filaments	wrap	
around	one	another	to	form	the	fibril	[10].	The	individual	filaments	have	a	lamellar	
cross-𝛽-sheet	 structure,	 composed	 of	 thousands	 of	 individual	 non-covalently	
associated	protein	or	peptide	subunits.	Amyloid	fibrils	are	inherently	non-crystalline,	
insoluble	 materials;	 this	 renders	 it	 difficult	 to	 determine	 their	 high-resolution	
molecular	 structures	 when	 using	 traditional	 methods,	 particularly	 x-ray	






and	 C-term	 segment	[61].	 Initial	 work	 by	 Tjenberg	 identified	 the	 A𝛽	 central	
hydrophobic	 core	 KLVFF	 as	 the	 key	 scaffold	 for	 designing	 disrupters	 of	 A𝛽$%	
fibrillization	[62].	They	also	showed	that	peptides	incorporating	a	short	A𝛽	fragment	









The	 electrochemical	 detection	 and	 kinetics	 of	 the	 aggregation	 of	 amyloid	 beta	
peptides	(A𝛽$%,	A𝛽$&)	using	three	different	voltammetric	techniques,	after	incubation	
at	80	𝜇M,	were	 investigated	[67].	There	are	 several	kinds	of	 aggregates,	 including	
disordered	or	amorphous	aggregates,	but	amyloid	fibrils	are	most	characteristic	[68].	
Hu	 et	 al.	 proposed	 the	 aggregation	mechanisms	 of	 A𝛽$&,	with	 and	without	 nuclei,	
where	 aggregation/	 disaggregation	 equilibrium	 is	 occurring	[69].	 During	 the	 A𝛽	
aggregation	process,	soluble	A𝛽	 peptides	are	known	 to	 change	 their	 conformation	













salt,	 25-37	 °C),	 the	 experimental	 qualitative	 consensus	 includes:	 (a)	 A𝛽$%	 rapidly	
forms	 amyloid	 fibrils	 at	 concentrations	 over	 100	 𝜇M	[72,	 73];	 and	 (b)	 at	 A𝛽$%	




mM,	 the	 same	 condition	 that	 induces	 protofibril	 association	[76].	 Salt-induced	
aggregation	has	also	been	observed;	e.g.	NaCl	at	concentrations	ranging	from	dozens	
to	 hundreds	 of	 millimolars	 can	 promote	 the	 lateral	 association	 of	 70	 𝜇M	 A𝛽$%	
protofibrils	[76].	 Recently,	 a	 coarse	 grain	 model	 was	 used	 to	 investigate	 the	
aggregation	of	75mer	A𝛽$&	oligomer,	and	the	salt	effect	[69].	
Strategies for AD treatment 
The	 complexity	 of	 A𝛽	 production	 and	 aggregation	 pathways,	 and	 the	 unknowns	
regarding	the	role	of	the	various	structures	in	the	development	of	AD,	partly	explain	
the	 remaining	 challenges	 in	 finding	 a	 treatment	 to	 slow	 or	 prevent	 this	 disease.	
Clearly,	 there	 remains	 a	 need	 to	 work	 on	 a	 fundamental	 understanding	 of	 A𝛽’s	
kinetics	 as	well	 as	on	 possible	 inhibitors	 that	may	 act	 at	 various	 points	 along	 the	
pathway	to	toxicity.	
Therapeutic strategies for decreasing A𝜷 production 
There	are	at	least	three	paths	to	reducing	A𝛽	production:	inhibiting	𝛽-	or	𝛾-secretase,	
and	 enhancing	 𝛼-secretase	 activity	[43].	 To	 ensure	 transport	 to	 the	 active	 site,	
enzyme	inhibitors	with	therapeutic	potential	should	preferably	be	smaller	than	700	
Da	[77].	











plaques	[80].	 It	 was	 reported	 that	 BACE1	 accumulates	 in	 swollen	 presynaptic	




with	 age	 in	 mouse,	 monkey,	 and	 human	 brains	 (18-92	 years	 of	 age)	[84].	 BACE	
protein	 levels,	 however,	 did	 not	 change	 with	 age,	 suggesting	 that	 an	 age-related	
increase	of	BACE	activity	contributes	to	the	increased	production	and	accumulation	
of	A𝛽	in	the	brain,	and	potentially	predisposes	humans	to	Alzheimer’s	disease	[84].	










from	 APP,	 𝛾-secretase	 has	 many	 other	 substrates	 and	 cleaves	 several	 other	
transmembrane	proteins	 including	the	notch	receptor-1,	necessary	 for	growth	and	
development	[85].	𝛾-secretase	 cuts	 C99	 to	 release	A𝛽,	which	 is	 secreted	 from	 the	






Therapeutic strategies for preventing A𝜷 aggregation 
Given	the	difficulty	of	controlling	A𝛽	production,	considerable	efforts	have	been	made	
to	prevent	A𝛽	aggregation	through	a	wide	range	of	potential	inhibitors.	
Phenolic-based non-peptidic anti-aggregation 
One	 strategy	 to	 mitigate	 AD	 may	 be	 the	 development	 of	 neuroprotective	 agents	
capable	 of	 reducing	 the	A𝛽	 aggregation	 process	 and/or	 inducing	 the	 formation	 of	
non-toxic	 A𝛽	 oligomers	[88].	 Since	 amyloid	 peptides	 are	 located	 in	 the	 brain,	 an	
effective	drug	and/or	its	metabolites	should	be	able	to	cross	the	blood-brain	barrier	
[89]	and	reach	the	central	nervous	system	(CNS).	Researchers	have	investigated	the	
interaction	 between	polyphenols	 and	 the	BBB	[90],	 as	well	 as	 the	 permeability	 of	
flavonoids	 and	 their	 known	 metabolites	 across	 the	 BBB	[91-93].	 Many	 natural	
molecules,	 extracted	 from	 plants	 and	 trees	 (green	 chemistry)	 display	 the	 key	
characteristics	 and	 properties	 (e.g.	 hydrophobicity,	 aromaticity	 and	 hydrogen	
bonding)	necessary	to	maximize	the	chances	of	mitigating	Alzheimer’s	disease.	These	


















load	[96-98].	Polyphenols	and	 their	derivatives,	 as	well	 as	 curcumin,	showed	anti-
aggregation	 activity	[99].	 Non-flavonoids	 showed	 higher	 anti-aggregation	 activity	
than	flavonoids.	Lakey-Beitia	et	al.	[83]	proposed	a	relationship	between	polyphenol	
structure	 and	 anti-aggregation	 activity,	 in	which	 polyphenols	with	more	 aromatic	





widely	 distributed	 in	 nearly	 all	 plant	 foods	 and	 beverages	[100].	 Tannins	 can	 be	
defined	as	a	unique	group	of	phenolic	metabolites	of	relatively	high	molecular	weight,	
with	the	ability	to	complex	strongly	with	carbohydrates	and	proteins	[100].	However,	
some	 tannins	 are	 not	 water-soluble	 compounds;	 some	 have	 molecular	 weights	
ranging	from	3,000	to	over	30,000	Da.	Tannins	can	be	divided	into	two	major	groups,	
hydrolysable	 and	 condensed	 tannins.	 The	 former	 involves	 two	 types	 of	 tannins,	
gallotannins	 and	 ellagitannins.	 Tannases	 are	 key	 enzymes	 in	 the	 degradation	 of	
gallotannins.	 Tannins	 have	 the	 highest	 number	 of	 hydroxyl	 groups	 among	




sequence	[97,	98].	Moreover,	 inhibitor	planarity	 is	 essential	 for	 increasing	 surface	
contact	with	A𝛽	peptides	[96].	Most	polyphenols	have	more	than	two	aromatic	rings,	
essential	for	𝜋-𝜋	stacking	interactions	with	hydrophobic	amino	acid	residues	of	A𝛽	
(Tyr,	 Phe),	 and	 at	 least	 three	 hydroxyl	 groups	 that	 form	 hydrogen	 bonds	 with	
hydrophilic	amino	acid	residues	of	A𝛽	(His6,	Ser8,	Tyr10,	His14,	Lys16)	[103].		
Ellagitannins	are	a	biologically	and	structurally	diverse	class	of	natural	products.	The	










Native	 to	 the	 monsoon	 forests	 of	 south-east	 Asia,	 turmeric	 is	 a	 perennial	 herb	
commonly	used	in	Indian,	Asian	and	Middle	Eastern	foods	[106].	Research	over	the	
last	half-century	has	revealed	several	important	functions	of	curcumin	[107].	Goel	et	
al.	[107]	 reported	 a	 comprehensive	 review	 of	 the	 literature,	 including	 a	 list	 of	
molecular	targets	and	ligands	which	interact	with	curcumin	[99].	Curcumin	showed	
a	wide	range	of	pharmacological	activities	such	as	anticancer	[108],	antioxidant	[109,	
110],	 antiinflammatory	[111,	 112],	 antiangiogenic	[113]	 and	 wound-healing	
effects	[114].	Curcumin	metabolites,	e.g.	biotransformed	to	dehydrocurcumin	(DHC)	
and	 tetrahydrocurcumin	 (THC),	 are	 subsequently	 converted	 to	monoglucoronides	
conjugates	[115].	Curcumin	differs	from	THC	which	lacks	𝛼,𝛽-unsaturated	carbonyl	
moiety	and	is	white	in	color,	and	is	bioavailable	after	administration	in	animals	[116].	
Interestingly,	 Aggarwal	 et	 al.	[116]	 reported	 several	 biological	 activities,	 including	
studies	showing	curcumin	to	be	more	active	than	THC	and	other	studies	showing	THC	
to	be	more	active	 than	curcumin.	Both	phenolic	OH	and	 the	𝛽-diketone	moiety	of	
curcumin	 are	 responsible	 for	 the	 antioxidant	 effects,	 a	 function	 of	 the	 type	 of	
radical	[117].	Aggarwal	et	al.	[118]	further	suggested	that	curcumin	may	mediate	its	
effect	 against	 AD	 through	 eight	 mechanisms.	 Those	 directly	 related	 to	 anti-
aggregation	 and/or	 disaggregation	 are:	 i)	 curcumin	 can	 modulate	 the	 formation,	
extension,	 and	 destabilization	of	 fA𝛽$%	 and	 fA𝛽$&	 in	 vitro	[101];	 ii)	 it	 could	 inhibit	
aggregated	as	well	as	disaggregated	fA𝛽$%	[99];	and	iii)	it	labels	amyloid	pathology	in	
vivo,	 disrupts	 existing	 plaques,	 and	 partially	 restores	 distorted	 neurites	 in	 an	 AD	
mouse	model	[119].		
A	recent	review	of	curcumin’s	mechanisms	of	action	in	AD	suggests	its	usefulness	as	





mg/ml	 at	 pH	6.96	[122].	 Although	 10	 or	 12	 g	 of	 curcumin	 administered	 orally	 in	
humans	 showed	 curcumin	 levels	 in	 serum	 to	 be	 approximately	 50	 ng/ml,	 this	
resulted	in	a	minimum	bioavailability	of	curcumin	in	the	blood	circulation	to	achieve	
its	therapeutic	effects	[123].	Consequently,	significant	efforts	were	made	to	increase	
curcumin	 solubility,	 bioavailability	 and	 stability	[121,	 122],	 e.g.	 the	 formation	 of	
cyclodextrin/curcumin	 complexes	 leading	 to	 an	 increase	 in	 curcumin’s	 water	
solubility	 by	 a	 factor	 of	 at	 least	 104	 at	 pH	 5	[124].	 Other	 ways	 of	 increasing	
bioavailability	 include	 making	 nanoparticles	[125];	 for	 example,	 NanoCurc,	 a	
nanoformulation	 of	 curcumin,	 showed	neuroprotective	 and	 neurorescue	 effects	 in	
neuronal	cultures	and	animals	[126].	
Among	 214	 tested	 compounds,	 curcuminoids,	 flavone-type	 flavonoids,	 and	
naphthoquinones	were	shown	to	be	potent	inhibitors	of	A𝛽	fibrilization	in	vitro	[127].	
Curcumin	 binds	 to	 the	 N-terminus	 (residues	 5-20)	 of	 A𝛽$&	 monomers	[58].	 The	
hydrophobic	C-terminus	of	A𝛽$&	has	long	been	considered	important	in	driving	fibril	
formation	[46].	 Curcumin	 directly	 binds	 with	 small	 amyloid-𝛽	 species	 to	 inhibit	
aggregation	and	fibril	formation	in	vitro	and	in	vivo	[99],	and	to	destabilize	preformed	
fibrils	at	concentrations	between	0.1	𝜇M	and	1.0𝜇M	[101,	128].	As	monitored	by	UV	




and	 disaggregated	 fibrillar	A𝛽$%	 (IC50=	 1.0	𝜇M)	[99].	 Curcumin	was	 a	 better	A𝛽40	
aggregation	 inhibitor	 than	 ibuprofen	 and	 prevented	A𝛽$&	 oligomer	 formation	 and	
toxicity	between	0.1	and	1.0	𝜇M	[99].	In	vivo	studies	showed	that	curcumin	injected	
peripherally	 into	 aged	 Tg	 mice	 crossed	 the	 blood-brain	 barrier	 and	 bound	 to	
plaques	[99].	Curcumin-treated	mice	had	noticeably	fewer	and	smaller	plaques,	i.e.,	a	
significant	reduction	in	plaque	size	of	about	30%	was	observed	after	seven	days	of	





Curcumin	 has	 also	 been	 the	 focus	 of	 intense	 research	 using	 a	 hybridization	
strategy	[132].	 Piperine	 (1-piperoylpiperidine)	 is	 an	 alkaloid	 extracted	 from	black	
pepper	 fruits	 (piper	nigrum)	 and	present	also	 in	 long	peppers	 (piper	 longum)	 and	
other	pepper	species	(piperaceae).	Piperine	 is	known	for	 its	ability	 to	enhance	the	
bioavailability	of	numerous	drugs	and	phytochemicals	[133].	 In	 the	 context	of	AD,	
Suresh	and	Srinivasan	orally	administered	500	mg	curcumin,	170	mg	piperine,	or	a	
combination	of	the	two	in	a	single	formulation	to	Wistar	male	albino	rats	[134].	They	




was	 also	 included,	 not	 only	 improved	 cognitive	 functioning	 in	 transgenic	 mouse	
models	of	AD,	but	also	decreased	A𝛽	levels	and	oligomerization	[135].	Recently,	novel	
curcumin	derivatives	were	proposed	as	potent	inhibitors	against	AD,	e.g.	protecting	





incidence	 of	 dementia,	 AD	 and	 Parkinson’s	 disease	[137].	 In	 particular,	 the	 main	
catechin	polyphenol	constituent	found	in	tea,	(-)-epigallocatechin-3-gallate	(EGCG),	
has	been	 shown	 to	exert	neuroprotective	activities	 in	a	wide	array	of	 cellular	and	
animal	models	of	neurological	disorders	[137].	EGCG	also	inhibits	A𝛽	aggregation	in	








An	 extensive	 replica-exchange	 molecular	 dynamics	 (REMD)	 simulation	 was	
performed	 to	 investigate	 the	 progress	 patterns	 of	 EGCG	 inhibition	 on	 the	A𝛽*.,&& 	
hexamer	[140].	Both	electrostatic	and	van	der	Waals	 interactions	were	 involved	 in	
the	 binding	 domain.	 In	 addition,	 quantum	 chemical	 methods	 showed	 that	 𝜋-𝜋	
stacking	interactions	are	critical	between	EGCG	and	peptides	[140].	The	polyphenol	
EGCG	efficiently	 inhibits	 the	 fibrillogenesis	of	amyloid-𝛽	by	directly	binding	to	the	
natively	 unfolded	 polypeptides	 and	 preventing	 their	 conversion	 into	 toxic,	 on-
pathway	aggregation	intermediates.	Formation	of	unstructured,	nontoxic	amyloid-𝛽	
oligomers	of	a	new	type,	rather	than	𝛽-sheet-rich	amyloids,	is	promoted;	this	suggests	








products	such	as	grapes,	berries,	and	wine	[144].	 Its	concentration	 is	a	 function	of	
geographical	 origin,	 variety,	 growing	 methods,	 and	 winemaking	 processes	[145].	
Moreno-Labanda	et	al.	showed	that	the	average	total	resveratrol	equivalent	content,	





about	 the	 cis-isomer’s	 pharmacological	 activity	[147].	 Resveratrol	 can	 induce	
protective	effects	in	neurodegenerative	conditions	such	as	AD	[148].	Surface	plasmon	





binds	 to	 the	 N-terminus	 (residues	 5-20)	 of	 A𝛽$&	 monomers	[58].	 Resveratrol	
promotes	 the	 non-amyloidogenic	 cleavage	 of	 the	 amyloid	 precursor	 protein,	
enhances	 clearance	 of	 amyloid	 beta-peptides,	 and	 reduces	 neuronal	 damage	[138,	
144].	 Because	 it	 has	 no	 effect	 on	 the	 A𝛽-producing	 enzymes	𝛽-	 and	𝛾-secretases,	
resveratrol	 does	 not	 inhibit	 A𝛽	 production;	 rather,	 it	 promotes	 intracellular	
degradation	 of	 A𝛽	 via	 a	 mechanism	 that	 involves	 the	 proteasome	[148].	 Neither	
resveratrol	nor	its	conjugated	metabolites	were	detectable	in	the	brain.	Nevertheless,	
resveratrol	 diminished	 plaque	 formation	 in	 a	 region-specific	 manner;	 the	 largest	





dependently	 inhibit	 A𝛽$&	 fibril	 formation	 and	 cytotoxicity,	 surprisingly	 it	 did	 not	
prevent	A𝛽$&	oligomerization	[150].	Feng	et	al.	 indicate	that	when	added	to	10	𝜇M	
A𝛽$&,	10	𝜇M	and	100	𝜇M	of	resveratrol	could	inhibit	over	50%	and	90%	of	A𝛽$&	fibril	





herbaceous	 and	 woody	 plants.	 Tannic	 acid	 reduces	 A𝛽	 production	 and	 inhibits	
amyloidogenic	APP	metabolism	in	neuron-like	cells	[152].	For	example,	tannic	acid	
administered	orally	to	transgenic	PSAPP	mouse	models	of	cerebral	amyloidosis	for	
six	 months	 raises	 the	 possibility	 that,	 by	 inhibiting	 𝛽-secretase	 activity	 and	
neuroinflammation,	 and	 hence	mitigating	 AD	pathology,		 dietary	 supplementation	
with	 TA	 may	 be	 prophylactic	 for	 AD	 [152].	 Tannic	 acid	 significantly	 inhibits	 the	





less	 than	0.1	𝜇M,	and	 the	 IC 3%	 in	 vitro	 of	0.012	and	0.022𝜇M	for	A𝛽$%	 and	A𝛽$&,	
respectively	[96,	101].		






the	 bioactivity	 of	 TA	[128].	 Experimental	 results	 also	 suggest	 that	 tau	 peptide	
interacts	 with	 TA	 by	 forming	 a	 hairpin	 structure,	 a	 feature	 for	 inhibiting	 tau	
polymerization	[155].	
Morin 
The	 effective	 concentrations	 (EC 3%)	 of	 myricetin,	 morin,	 and	 quercetin	 for	 the	
formation,	extension	and	destabilization	of	A𝛽	fibrils	were	found	to	be	in	the	order	of	
0.1	 𝜇M	 to	 1	 𝜇M	[156].	 Atomistic,	 explicit-solvent	 molecular	 dynamics	 (MD)	
simulations	 were	 used	 to	 identify	 the	 mechanism	 through	 which	 A𝛽	 fibril	 is	
destabilized	by	morin,	an	effective	anti-aggregation	flavonoid	[157].	Morin	was	found	
to	 bind	 to	 the	 ends	of	 the	 fibrils,	 thereby	 blocking	 the	 attachment	 of	 an	 incoming	
peptide.	It	also	penetrated	the	hydrophobic	core	to	disrupt	electrostatic	interactions	
between	 oppositely-charged	 side	 chains	 of	 Asp23	 and	 Lys28	 (i.e.	 a	 salt	 bridge	
interaction)	and	interfere	with	backbone	hydrogen	bonding	[157,	158].	
Other natural green molecules (e.g. anthocyanins, apigenin, catechin, gallotannins, 














or	 Sambucus	 canadensis	 L)	 was	 also	 described	 as	 far	 back	 as	 the	 early	 20th	
century	[161].	 Rutin	 has	 a	molecular	weight	 of	 610.52	 g/mol	 and	 its	 solubility	 in	
water	 is	 0.13	 g/L.	 Sabogal-Guáqueta	 et	 al.	[162]	 showed	 that	 quercetin	 decreases	
extracellular	𝛽-amyloidosis,	supported	by	a	significant	reduction	in	the	paired	helical	
filament	 (PHF),	 A𝛽$%	 and	 A𝛽$&	 levels	 as	 well	 as	 a	 decrease	 in	 BACE1-mediated	
cleavage	 of	 APP	 (into	 CTF𝛽).	 It	 was	 also	 suggested	 that	 rutin’s	 effectiveness	 in	
preventing	 cognitive	 deficits	 might	 be	 beneficial	 in	 the	 treatment	 of	 sporadic	
dementia	of	Alzheimer	type	(SDAT)	[163].		
Several	MD	 trajectories	were	 analyzed,	 describing	 the	 evolution	of	 the	GNNQQNY	
heptapeptide	decamer	fragment	taken	from	its	crystal	structure,	both	singly	and	in	
the	 presence	 of	 myricetin	 and	 kaempferol,	 two	 naturally-occurring	 polyphenols	
found	to	be	strong	and	weak	aggregation	inhibitors,	respectively	[164].	The	binding	
affinity	 of	 A𝛽$%	 and	A𝛽$&	 peptides	with	 342	 compounds	 derived	 from	Vietnamese	
plants	 was	 investigated	 using	 a	 docking	 technique	 combined	 with	 the	 molecular	
mechanic	Poisson-Boltzmann	surface	area	method	[89].	Of	 these	 compounds,	only	
five	ligands	showed	a	high	binding	affinity	to	monomers	and	mature	fibrils	of	amyloid	
peptides,	 including	 one	 flavone,	 hinokiflavone	[89].	 Oxidized	 flavonoids	 generally	




Rigacci	 et	 al.	[165]	 reported	 that	 the	 oleuropein	 polyphenol	 eliminates	 the	




protofibrils,	 which	 are	 structurally	 different	 from	 typical	 A𝛽$&	 fibrils.	 They	 also	
showed	 that	oleuropein	aglycon	 is	most	effective	when	present	at	 the	 start	of	 the	
aggregation	process	[165].	These	findings	suggest	that	flavonoids	-—	and	particularly	
myricetin	 —	 exert	 an	 anti-amyloidogenic	 effect	 in	 vitro	 by	 preferentially	 and	




closed	 conformer	[167].	 Natural	 flavonoids	 act	 as	 non-peptidic	 BACE-1	 inhibitors.	
The	calculated	50%	inhibitory	concentrations	(IC50)	were	as	follows;	myricetin	(2.8	
𝜇M)	<	quercetin	(5.4	𝜇M)	<	kaempherol	(14.7	𝜇M)	<	morin	(21.7	𝜇M)	<	apigenin	
(38.5	 𝜇M)	[166].	 Moreover,	 the	 polyphenols’	 anti-amyloidogenic	 and	 fibril-




reach	 the	 mammalian	 brain	 within	 minutes	 of	 their	 introduction	 into	 the	
stomach	[168].	A	diet	enriched	in	blueberries,	a	fruit	rich	in	anthocyanins,	prevents	
cognitive	 deficits	 in	 APP/PS1	 transgenic	 mice	 with	 no	 alterations	 in	 A𝛽	
deposits	[169].	 A	 recent	 review	 showed	 that	 terminalia	 chebula	 extracts	 and	 its	
constituents	have	acetylcholinesterase	inhibitors	(AChEIs)	and	antioxidant	and	anti-
inflammatory	 effects,	 all	 of	 which	 are	 relevant	 in	 the	 treatment	 of	 Alzheimer’s	
disease	[170].	
Green chemistry: polyphenol intermediate size anti-aggregation 
To	 expand	 the	 number	 of	 polyphenol	 candidates	 in	 AD	 treatment,	 it	 is	 useful	 to	
examine	their	industrial	applications.	For	example,	some	polyphenols	(e.g.	tannins)	
used	in	the	corrosion	inhibition	and	paper	industries	display	remarkable	dispersive	










proteins,	 as	 they	 form	 tannin/protein	 complexes	 leading	 to	 either	 enzyme	
deactivation	 or	 protein	 insolubility.	 For	 example,	 nineteen	 phenolic	 compounds	
exhibited	strong	inhibition	against	prolyl	endopeptidase	(PEP),	an	enzyme	that	may	
play	 a	 functional	 role	 in	 amyloidgenesis	 in	 the	 brain	[171].	 Of	 those,	 TGG	 (IC50=	
157.2x10-9	M)	 and	 corilagin	 (IC50=	 236.5x10-9)	 exhibited	 strong	 inhibition	 against	
PEP	[172].	 These	 molecules	 share	 many	 of	 the	 properties	 observed	 in	 molecules	
presented	in	the	previous	sections,	suggesting	that	naturally-occurring	polyphenols	
should	be	more	extensively	studied	in	the	context	of	AD.	These	molecules	are	also	
interesting	 because	 they	 are	 natural	 green	 polyphenols	 extractable	 through	 green	
chemistry,	and	act	as	cofactors	in	the	association	of	macromolecules.	The	molecular	
structures	 of	 TGG	 and	 corilagin	 were	 determined	 using	 the	 predictive	 PM3	

















TGGT	 cavity	 is	 large	 enough	 to	 contain	 a	 segment	 of	 the	 amyloid-beta	 (A𝛽)	










sibiricum	[181,	 182].	 Recently,	 Li	 et	 al.	[182]	 reported	 that	 corilagin	 has	 been	
identified	 in	 as	many	 as	 53	 plants	 worldwide.	 Corilagin’s	 solubility	 has	 not	 been	
clearly	 defined	 in	 the	 literature.	 For	 example,	 at	 pH	 5.0	 its	 solubility	 in	 aqueous	





and	chair,	with	 final	heats	of	 formation	of	 -645.61,	 -629.09	and	 -623.57	kcal/mol,	
respectively	[175,	176].	The	difference	in	the	final	heat	of	formation	between	the	boat	














properties	[182],	 including	 usefulness	 in	 antioxidant	[181,	 185],	 anti-
hypertensive	[186,	 187],	 anticancer	 /	 antitumor	[182,	 188],	 anti-inflamatory	[188-
192],	 and	 antibacterial/antiviral	[193-196]	 treatments.	 It	 is	 also	 a	 potential	
treatment	for	radiation-induced	brain	injuries	(RIBI)	[197,	198],	as	well	as	in	Type	II	
diabetes	 management	[182,	 199].	 Moreover,	 corilagin	 may	 inhibit	 the	 growth	 of	
various	microorganisms,	including	bacteria,	fungi,	and	viruses	[182].	The	cytotoxicity	
of	 corilagin	 was	 tested	 using	 the	 XTT	 assay;	 the	 50%	 cytotoxic	 concentration	 of	
corilagin	for	African	green	monkey	kidney	(Vero)	cells	was	37.4	+/-6.7	𝜇M	[200].	It	







BACE1	 in	 a	 silico	 docking	 model	 system	[201].	 Two	 compounds,	 geraniin	 and	
corilagin,	 isolated	 from	 the	 most	 active	 EtOAc	 fraction	 of	 G.	 thunbergii,	 exhibited	
predominant	in	vitro	inhibition	against	𝛽-secretase,	with	IC50	values	of	4.0x10-6	and	





and	 inflammatory	 responses	 in	 PC12	 cells.	 Pretreatment	 with	 corilagin	 before	
exposure	to	A𝛽&3,63	increased	cell	viability	in	a	dose-dependent	manner	by	68.67%,	
80.78%,	and	90.87%	at	0.1	𝜇M,	1	𝜇M,	and	10𝜇M,	respectively	[192].	These	findings	
suggest	 that	 attenuation	 of	 A𝛽&3,63-induced	 inflammatory	 responses	 by	





herpes	 simplex	 encephalitis-induced	 pathological	 changes.	 Interestingly,	 Yeo	 et	




𝜇g/mL,	 respectively	[196].	 Phyllanthus	 amarus	 extracts	 potently	 inhibit	 HIV-1	
replication	in	HeLa	CD4+	cells	with	50%	effective	concentration	values	(EC50)	ranging	
from	 0.9	 to	 7.6𝜇g/ml	[194].	 A	 gallotannin-enriched	 fraction	 showed	 enhanced	
activity	(0.4𝜇g/ml),	with	the	purified	gallotannins	geraniin	and	corilagin	being	most	
active	 (0.24𝜇g/ml)	[194].	 Corilagin	 isolated	 from	 medicinal	 plants,	 such	 as	




induced	 brain	 injuries	 in	 mice	[198].	 Morris	 water	 testing	 indicated	 corilagin	
improved	the	neurocognitive	deficits	in	RIBI	mice	[198].	In	addition,	microglia	play	a	
major	role	in	pathological	events	leading	to	inflammation-related	diseases,	such	as	
radiation-induced	 brain	 injuries,	 Alzheimer’s	disease,	 and	multiple	 sclerosis	[197].	
Data	 from	Dong	 et	 al.	[197]	 suggest	 that	 corilagin	 inhibits	 activation	 of	 radiation-
induced	 microglia	 through	 suppression	 of	 the	 NF-kB	 pathway,	 indicating	 the	
compound’s	viability	as	a	potential	RIBI	treatment.	
Pharmacological	properties	of	natural	polyphenols	(curcumin,	corilagin,	and	TGG)	
Pharmacological properties	 Curcumin	 Ref.	 Corilagin	 Ref.	 TGG	 Ref.	
Anticancer / Antitumor	 X	 [108]	 X	 [182, 188]	   
Antioxidant	 X	 [31, 109, 
110]	
X	 [181, 185]	 X	  
Anti-inflammatory	 X	 [111, 112]	 X	 [188–192]	   
Cardiovascular /	       
antihypertensive	   X	 [186, 187]	   
Antibacterial / antiviral	   X	 [182, 193–
196]	
  
Antiangiogenic	 X	 [113]	 X	    
Wound healing	 X	 [114]	     
Managing Type II diabetes	   X	 [182, 199]	   
Radiation-induced	       
brain injury (RIBI)	   X	 [197, 198]	   




Other	 X	 [107, 116]	  [172, 182]	 X	 [172]	
	
To	 summarize,	 these	 green	 molecules	 (e.g.	 TGG	 and	 corilagin)	 have	 very	 similar	
molecular	structures	and	properties,	including	three	phenolic	rings	for	𝜋-𝜋	stacking	




complementary	 structures	 (rigid	 vs.	 more	 flexible)	 are	 relevant	 in	
nucleation/fibrillation/aggregation	 inhibition	 and/or	 altering	 the	 toxicity	 of	
oligomers,	in	the	context	of	neurodegenerative	Alzheimer’s	disease.	
CONCLUDING REMARKS 
Many	 green	 chemistry	 candidates	 have	 been	 proposed	 for	mitigating	 Alzheimer’s	
disease	 (AD).	 Phenolic	molecules	 such	 as	 flavonoids,	 non-flavonoids,	 gallotannins,	
elagitannins,	 grape	 seed	 extracts	 (GSE),	 grape	 juice,	 etc.,	 have	 the	 potential	 to	
modulate	 AD	 neuropathology	 and	 cognitive	 dysfunction	 through	 multiple	
mechanisms,	 including	 modulating	 oxidation	 and	 inflammation,	 modulating	 A𝛽	
metabolism,	catabolism	and	oligomerization,	and	directly	influencing	brain	activities.	
Moreover,	 experimental	 evidence	 suggests	 that	polyphenols	which	 target	multiple	
disease	mechanisms	may	have	a	stronger	likelihood	of	therapeutic	efficacy.	Despite	
strong	 research	 and	 theoretical	 evidence,	 these	 molecules	 have	 not	 yielded	 the	
anticipated	clinical	trial	results.	Nevertheless,	this	fact	should	not	lead	researchers	to	
entirely	disregard	 this	 rich	 compound	 family,	with	 its	potential	 candidates	 for	AD	
therapy. 	
Indeed,	 various	 compounds	already	used	 in	manufacturing	should	be	 revisited	 for	






These	 molecules	 possess	 key	 characteristics	 and	 properties	 (hydrophobicity,	
aromaticity,	 and	 hydrogen	 bonding)	 important	 in	 mitigating	 Alzheimer’s	 disease.	
They	 may	 be	 extracted	 from	 plants	 and	 trees	 through	 green	 chemistry,	 are	 of	
intermediate	size	(meaning	they,	and/or	their	metabolites,	may	cross	the	blood-brain	
barrier),	have	a	hydrophobic	functional	character,	associate	quickly	with	protein,	and	
their	 molecular	 complexes	 exhibit	 a	 colloidal	 behavior	 in	 terms	 of	 stability	 and	
kinetics	of	association.	Reported	to	have	several	pharmacological	activities	and	low	
toxicity,	 corilagin	 might	 alter	 the	 nucleation	 process	 of	 formation	 of	
protofibril/fibril/fiber,	hence	minimizing	and/or	altering	aggregate/cluster/plaque	
structures.	 In	 addition,	 corilagin	 and	 its	 close	 analogue,	 TGG,	 may	 help	 reduce	
oligomer	cytotoxicity.		
Although	we	are	unaware	of	any	data	in	the	literature	on	brain	levels	for	the	proposed	
intermediate	size	of	natural	polyphenols	(i.e.	corilagin	and	TGG)	when	administered	
orally	to	human	subjects,	green	phenolic	molecules	perform	well	in	other	industries	
and,	hence,	should	be	further	investigated	as	potential	candidates	in	the	fight	against	
AD.	
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